CT Children's CLASP Guideline *Early Onset Pubic Hair and/or Body Odor*

INTRODUCTION	Premature pubarche (PP) refers to the early onset of pubic hair, body odor, and/or axillary hair in girls less than 8 years of age and boys less than 9 years. Premature adrenarche (PA) refers to PP that is also associated with increasing levels of adrenal androgens that fall within pubertal ranges. There is no accelerated growth velocity in either PP or PA. PP and PA need to be distinguished from other rare conditions that require treatment, including late onset congenital adrenal hyperplasia (CAH), virilizing adrenal or gonadal tumors, or exogenous exposure to androgens. In these rare conditions, there will often be rapid virilization <i>and</i> accelerated linear growth velocity.		
	Idiopathic PA is more commonly observed in girls by a ratio of 9:1. Although PA was once thought of as a benign condition, newer studies are linking PA with functional hyperandrogenism, polycystic ovarian syndrome, insulin resistance, Type II diabetes, and metabolic syndrome. Early identification and education of healthy lifestyle choices are encouraged.		
INITIAL	INITIAL EVALUATION:		
EVALUATION	Careful review of the growth chart and calculation of the growth rate		
AND MANAGEMENT	 Linear growth rate in PA and PP is within 2.5 SDs of normal without evidence of a linear growth spurt 		
History and physical exam			
	 Should include chronologic details of the onset of the changes noted and sexual maturity staging (see Clinician Guide: Sexual Maturity Staging) 		
	 Assess for rapid virilization (e.g., rapid increase in pubertal hair growth, new acne) and accelerated linear growth velocity 		
	 May indicate rare conditions such as late onset congenital adrenal hyperplasia (CAH), virilizing adrenal or gonadal tumors, or exogenous exposure to androgens 		
	 Family history of precocious puberty, congenital adrenal hyperplasia, hirsutism/acne, polycystic ovarian syndrome, Type II diabetes, or early cardiovascular disease 		
	Girls 8 years of age/boys 9 years of age:		
	 No laboratory evaluation needed unless there are concerns for rapid 		
	virilization, rapid height acceleration, and/or rapid pubertal advancement		
	during the observational period		
	Laboratory evaluation:		
	 Indicated for: All girls up to 7.99 years of age and all boys up to 8.99 years of age AND 		
	 All girls up to 7.99 years of age and all boys up to 8.99 years of age AND Girls 8 years of age and boys 9 years of age with rapid virilization, rapid height acceleration, and/or rapid pubertal advancement 		
	 Fasting 8 AM levels of DHEA-S, total testosterone, and 17- 		
	hydroxyprogesterone		
	 If there is evidence on exam of true precocious puberty (breast 		
	development in girls or testicular enlargement in boys):		
	 Obtain Pediatric FSH/LH for both boys and girls Add estradial ultra consitive measurements for sirls 		
	 Add estradiol ultra-sensitive measurements for girls 		



	 *Interpretation of laboratory values in those with PP or PA: 		
	 PP: normal DHEA-S level and total testosterone level <20 ng/dL 		
	 PA: DHEA-S level of 40-150 mcg/dL and total testosterone level <20 ng/dL 		
	 Since radiologists interpret bone ages (BAs) differently than pediatric endocrinologists and BA measurements are often advanced in children with PA, we DO NOT recommend obtaining a BA as part of the initial evaluation. The results of the recommended basal hormone levels will suffice to distinguish children who need further evaluation by a pediatric endocrinologist. 		
	INITIAL MANAGEMENT:		
	 For children with BMI >85th percentile, counseling on healthy lifestyle and obesity prevention (see Obesity & Screening for Co-Morbidities CLASP tool) 		
	All children less than 4 years of age:		
	• Refer to Endocrine (see When to Refer)		
	 Girls between 4-7.99 years of age/boys 4 – 8.99 years of age: If labs are normal, clinical monitoring is appropriate 		
	 If laboratory results consistent with diagnosis of PP or PA, patient to be followed clinically with 		
	primary care provider every 6 months		
	 Monitor for evidence of height acceleration, precocious puberty (i.e., breast development in girls, testicular enlargement in boys) and/or rapid virilization Offer education to patients and families (see Family Handout: Premature Adrenarche) 		
	Girls 8 years of age/boys 9 years of age:		
	 These are the normal ages for children to develop adrenarche. Give reassurance Carefully observe for signs of rapid virilization, height acceleration and/or rapid pubertal progression (i.e., significant change in breast development in girls, or rapid testicular enlargement in boys) for 4-6 months 		
WHEN	All children less than 4 years of age:		
TO REFER	Routine referral to Endocrinology		
	Girls between 4-7.99 years of age/boys 4 – 8.99 years of age:		
	Routine referral to Endocrinology if:		
	 laboratory results above ranges for PP or PA, or there are concerns for rapid virilization, rapid height acceleration, and/or rapid pubertal advancement 		
	Girls 8 years of age/boys 9 years of age:		
	Routine referral to Endocrinology is only recommended for patients for whom there are concerns		
	for rapid virilization, rapid height acceleration, and/or rapid pubertal advancement		
	If patient with a BMI ≥95 th percentile:		
	Refer to Weight Management Program via the Obesity & Screening for Co- Morbidities Tool		
HOW	Referral to Endocrinology via CT Children's One Call Access Center		
TO REFER	Phone: 833.733.7669 Fax: 833.226.2329 For more information on how to place referrals to Connecticut Children's, click <u>here.</u>		
	is more mornation of now to place referrais to connecticat children's, click nere.		



	 Information to be included with the referral: Notes from the initial and follow-up visits with the PCP Complete growth charts Relevant laboratory and diagnostic studies 		
WHAT TO EXPECT	 What to expect from CT Children's Visit: History, physical exam Evaluation of prior laboratory testing and growth chart Additional labs, if appropriate Bone Age obtained and read by pediatric endocrinologist, if appropriate 	 Other imaging studies, if appropriate Initiation of treatment, if appropriate Comprehensive patient education 	

